📊 MLSS Key Takeaways
Is Milestone Scientific Inc.. (MLSS) a Good Investment?
Milestone Scientific operates with severely negative operating margins (-38.3%) despite healthy gross margins (72.3%), indicating structural operational inefficiency that is unsustainable. The company's revenue base is minimal ($2.2M) with negligible growth (4.0% YoY) while net losses are accelerating (-21.4% YoY), creating a deteriorating fundamental picture with limited financial runway.
Despite a strong 71% gross margin and no long‑term debt, Milestone Scientific remains structurally unprofitable with widening losses and negative free cash flow. Slow 4% revenue growth, limited cash ($1.11M) versus sizable operating burn (~$2.9M) imply a short runway and high dilution/going‑concern risk absent a sharp acceleration in sales or material cost reductions.
Why Buy Milestone Scientific Inc.. Stock? MLSS Key Strengths
- Gross margin of 72.3% demonstrates underlying product viability and pricing power
- Positive operating cash flow ($86.8K) and free cash flow ($85.2K) despite accounting losses
- Zero long-term debt provides financial flexibility and eliminates refinancing risk
- High gross margin indicating attractive unit economics
- Debt-free balance sheet reduces financial risk
- Asset-light model with minimal capex needs
MLSS Stock Risks: Milestone Scientific Inc.. Investment Risks
- Operating margin of -38.3% reflects unsustainable cost structure relative to revenue base
- Net losses accelerating 21.4% YoY coupled with only 4.0% revenue growth trajectory
- Quick ratio of 0.79x indicates liquidity pressure; minimal cash buffer ($1.2M) insufficient for small, unprofitable operator
- Severely negative ROE (-36.8%) and ROA (-10.5%) indicate shareholder value destruction
- Revenue base of $2.2M too small to support overhead; no evidence of turnaround plan or management conviction (zero insider filings)
- Short cash runway given sustained operating cash burn
- Persistent negative operating margin with limited scale
- Potential dilution or going-concern risk if financing is required
Key Metrics to Watch
- Operating margin trend—requires return to positive territory for viability
- Revenue growth acceleration—4% YoY is insufficient to justify current cost structure
- Operating cash burn rate—monitor if positive FCF deteriorates given minimal equity cushion
- Quarterly revenue growth and reorder momentum
- Operating cash flow and cash runway (cash to burn)
Milestone Scientific Inc.. (MLSS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 3.9% FCF margin may limit capital allocation flexibility.
MLSS Profit Margin, ROE & Profitability Analysis
MLSS vs Healthcare Sector: How Milestone Scientific Inc.. Compares
How Milestone Scientific Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Milestone Scientific Inc.. Stock Overvalued? MLSS Valuation Analysis 2026
Based on fundamental analysis, Milestone Scientific Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Milestone Scientific Inc.. Balance Sheet: MLSS Debt, Cash & Liquidity
MLSS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Milestone Scientific Inc..'s revenue has declined by 13% over the 5-year period, indicating business contraction. The most recent EPS of $-0.06 indicates the company is currently unprofitable.
MLSS Revenue Growth, EPS Growth & YoY Performance
MLSS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.2M | -$839.9K | $-0.01 |
| Q3 2025 | $2.4M | $223.6K | $-0.01 |
| Q2 2025 | $1.9M | N/A | N/A |
| Q1 2025 | $2.2M | N/A | N/A |
| Q3 2024 | $2.1M | -$1.5M | N/A |
| Q2 2024 | $1.9M | $223.6K | N/A |
| Q1 2024 | $2.2M | -$1.3M | N/A |
| Q3 2023 | $2.1M | -$1.5M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Milestone Scientific Inc.. Dividends, Buybacks & Capital Allocation
MLSS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Milestone Scientific Inc.. (CIK: 0000855683)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MLSS
What is the AI rating for MLSS?
Milestone Scientific Inc.. (MLSS) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 85% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MLSS's key strengths?
Claude: Gross margin of 72.3% demonstrates underlying product viability and pricing power. Positive operating cash flow ($86.8K) and free cash flow ($85.2K) despite accounting losses. ChatGPT: High gross margin indicating attractive unit economics. Debt-free balance sheet reduces financial risk.
What are the risks of investing in MLSS?
Claude: Operating margin of -38.3% reflects unsustainable cost structure relative to revenue base. Net losses accelerating 21.4% YoY coupled with only 4.0% revenue growth trajectory. ChatGPT: Short cash runway given sustained operating cash burn. Persistent negative operating margin with limited scale.
What is MLSS's revenue and growth?
Milestone Scientific Inc.. reported revenue of $2.2M.
Does MLSS pay dividends?
Milestone Scientific Inc.. does not currently pay dividends.
Where can I find MLSS SEC filings?
Official SEC filings for Milestone Scientific Inc.. (CIK: 0000855683) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MLSS's EPS?
Milestone Scientific Inc.. has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MLSS a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Milestone Scientific Inc.. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MLSS stock overvalued or undervalued?
Valuation metrics for MLSS: ROE of -36.8% (sector avg: 15%), net margin of -38.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MLSS stock in 2026?
Our dual AI analysis gives Milestone Scientific Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MLSS's free cash flow?
Milestone Scientific Inc..'s operating cash flow is $86.8K, with capital expenditures of $1.6K. FCF margin is 3.9%.
How does MLSS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -38.8% (avg: 12%), ROE -36.8% (avg: 15%), current ratio 1.51 (avg: 2).